The settlement includes all persons or entities who or which (i) purchased or otherwise acquired the common stock of Marrone Bio Innovations Inc directly in or traceable to the Company’s August 1, 2013 initial public offering pursuant to Marrone Bio Innovations Inc’s Form S-1 Registration Statement, dated July 1, 2013, and its Prospectus, dated August 1, 2013; (ii) purchased or otherwise acquired Marrone Bio Innovations Inc common stock directly in or traceable to the Company’s secondary offering pursuant to Marrone Bio Innovations Inc’s Form S-1 Registration Statement, dated May 16, 2014, and its Prospectus dated June 5, 2014; and (iii) purchased or otherwise acquired Marrone Bio Innovations Inc common stock on the open market between August 1, 2013 and November 10, 2015.

September 27, 2016 - The court approved the settlement and entered the orders approving the plan of allocation, the motion for attorneys’ fees and expenses, and dismissing the action with prejudice.

July 8, 2016 - The court preliminarily approved the settlement.

June 16, 2016 - Parties filed a stipulation of settlement.

January 11, 2016 - The lead plaintiff filed a second amended consolidated complaint.

September 1, 2015 - The lead plaintiff filed an amended consolidated complaint.

February 13, 2015 - Lead plaintiff and lead counsel were appointed and all cases were consolidated.

November 4, 2014 - Lead plaintiff motions were filed.

September 5, 2014 - An investor in shares of Marrone Bio Innovations Inc (NASDAQ: MBII) filed a lawsuit in the U.S. District Court for the Eastern District of California against Marrone Bio Innovations Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between March 6, 2014 and September 2, 2014.

According to the complaint the plaintiff alleges on behalf of purchasers of Marrone Bio Innovations Inc (NASDAQ: MBII) common shares between March 6, 2014 and September 2, 2014, that the defendants violated Federal Securities Laws.

More specifically, the plaintiff claims that Defendants made allegedly false and/or misleading statements and/or failed to disclose that Marrone Bio Innovations Inc’s financial statements contained errors related to the improper recognition of revenues, that Marrone Bio Innovations Inc lacked adequate internal controls over financial reporting, and that as a result of the foregoing, Marrone Bio Innovations Inc’s financial statements were allegedly materially false and misleading at all relevant times.

Marrone Bio Innovations Inc reported that its annual Total Revenue rose from $7.14 million in 2012 to $14.54 million in 2013 and that its Net Loss declined from $38.79 million in 2012 to $28.49 million in 2013. Shares of Marrone Bio Innovations Inc (NASDAQ: MBII)

On September 3, 2014, Marrone Bio Innovations Inc announced that, at the recommendation of management, the Audit Committee of its Board of Directors has commenced an internal investigation after management learned of documents calling into question the recognition of revenue in the fourth quarter of 2013 for an $870,000 transaction. Marrone Bio Innovations Inc said its Audit Committee has retained independent legal advisers to assist it in this investigation. Additionally, the Audit Committee has determined that the company's financial statements for the fiscal year ended December 31, 2013, the unaudited interim financial statements for the three month period ended March 31, 2014 and the three- and six- month periods ended June 30, 2014, should no longer be relied upon as being in compliance with generally accepted accounting principles.

Shares of Marrone Bio Innovations Inc (NASDAQ: MBII) declined from $18.65 per share in January 2014 to as low as $2.80 per share on September 5, 2014.